Residency · Residency · Nuclear Medicine

Non-FDG PET Radiopharmaceuticals

Overview

While FDG remains the dominant PET tracer in clinical practice, it has significant limitations, including non-specificity for malignancy and low sensitivity for certain tumor types. Non-FDG PET radiopharmaceuticals address these gaps by targeting specific molecular pathways beyond glucose metabolism, including amino acid transport, bone turnover, receptor expression, membrane synthesis, and neurotransmitter systems. The expanding repertoire of non-FDG tracers reflects the broader growth of precision medicine and the theranostic paradigm.

Ga-68 DOTATATE (and DOTATOC/DOTANOC)

Mechanism and Target

The DOTA-peptide family of tracers targets somatostatin receptors (SSTRs), which are overexpressed on the surface of neuroendocrine tumor cells. DOTATATE (DOTA-Tyr3-octreotate) has the highest affinity for SSTR2, the predominant receptor subtype on well-differentiated NETs. DOTATOC (DOTA-Tyr3-octreotide) binds both SSTR2 and SSTR5, while DOTANOC (DOTA-NaI3-octreotide) has the broadest receptor profile, binding SSTR2, 3, and 5. All three are labeled with Ga-68 through the DOTA macrocyclic chelator.

Production

Ga-68 is obtained from a Ge-68/Ga-68 generator that operates in secular equilibrium (Ge-68 has a half-life of 271 days, vastly exceeding the 68-minute half-life of Ga-68). Alternatively, cyclotron-produced Ga-68 is increasingly available and offers higher yields with longer production runs. Ga-68 decays by positron emission (89%) with a half-life of 68 minutes. Kit-based preparation is available, with NETSPOT being the FDA-approved kit for Ga-68 DOTATATE.

Clinical Applications

The primary indication for Ga-68 DOTATATE PET/CT is imaging of neuroendocrine tumors, including staging, restaging, and selection of patients for peptide receptor radionuclide therapy (PRRT). It has dramatically superior sensitivity and specificity compared to the older In-111 octreotide scan (OctreoScan). Additional applications include meningioma, paraganglioma, pheochromocytoma, and in some cases medullary thyroid cancer. The normal biodistribution shows the highest uptake in the spleen (which has dense SSTR expression), followed by the adrenal glands, pituitary, kidneys and ureters/bladder (excretion), liver, mild thyroid uptake, and the uncinate process of the pancreas (physiologic SSTR2 expression). Important pitfalls include normal uncinate process uptake (which should not be confused with a pancreatic NET), splenunculi and accessory spleens, and inflammatory lymph nodes.

PSMA-Targeted PET Agents

Ga-68 PSMA-11

Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is markedly overexpressed on the surface of prostate cancer cells. Ga-68 PSMA-11 (also known as Ga-68 HBED-CC-PSMA) is a small-molecule inhibitor of PSMA labeled with Ga-68 through the HBED-CC chelator. It is FDA-approved for prostate cancer imaging in two clinical settings: biochemical recurrence after definitive treatment and initial staging of high-risk disease.

F-18 Piflufolastat (DCFPyL)

F-18 piflufolastat (marketed as Pylarify) is an F-18-labeled PSMA-targeted small molecule. Its longer half-life of 110 minutes (compared to Ga-68's 68 minutes) allows centralized production and broader distribution. The lower positron energy of F-18 also provides better counting statistics and higher image quality. It is FDA-approved for the same indications as Ga-68 PSMA-11.

F-18 Flotufolastat (rhPSMA-7.3)

F-18 flotufolastat is a radiohybrid PSMA ligand that uniquely incorporates both an F-18 label and a chelator site, enabling potential theranostic pairing with therapeutic radionuclides. It is FDA-approved for prostate cancer imaging and features rapid renal clearance, allowing early imaging at approximately 60 minutes post-injection.

Normal Biodistribution of PSMA Agents

All PSMA-targeted agents demonstrate intense physiologic uptake in the lacrimal glands and salivary glands (parotid and submandibular), high renal uptake due to proximal tubule PSMA expression with urinary excretion, moderate small bowel uptake (brush border PSMA/FOLH1 expression), and mild to moderate liver uptake. A particularly important source of false-positive findings is PSMA-expressing neural tissue in ganglia, including the celiac, stellate, and cervical ganglia.

PSMA PET Pitfalls

Ganglia uptake, particularly in the celiac and stellate ganglia, can convincingly mimic retroperitoneal or mediastinal lymph node metastases. PSMA is not expressed in all prostate cancers -- neuroendocrine differentiation and treatment-emergent small cell prostate cancer may be PSMA-negative. Furthermore, PSMA is not prostate-specific: it is expressed in several non-prostatic malignancies including renal cell carcinoma, hepatocellular carcinoma, breast cancer, glioma, and some sarcomas. Benign conditions such as Paget disease, healing fractures, and desmoid tumors can also show PSMA uptake.

F-18 NaF (Sodium Fluoride)

Mechanism

F-18 sodium fluoride (NaF) is a bone-seeking PET agent in which the fluoride ion exchanges with hydroxyl groups in the hydroxyapatite crystal lattice of bone. Its uptake reflects both osteoblastic activity and regional blood flow, analogous to the mechanism of Tc-99m MDP but with a substantially higher bone-to-background ratio. NaF is excreted renally, and imaging is performed at 45 to 60 minutes post-injection.

Clinical Applications

NaF PET/CT offers higher sensitivity for skeletal metastasis detection than conventional Tc-99m bone scan, along with superior spatial resolution and the ability to quantify tracer uptake. When combined with CT, it is also useful for evaluating benign bone disease. The normal biodistribution includes skeletal uptake (especially the axial skeleton and joints) and renal/bladder activity. Despite its superior diagnostic performance, NaF PET/CT remains limited in clinical adoption due to cost, availability, and reimbursement constraints.

Comparison with Tc-99m MDP

NaF PET/CT outperforms Tc-99m MDP bone scan in sensitivity, spatial resolution, and quantification capability. However, Tc-99m MDP remains far more widely available, costs less, and has well-established interpretation criteria refined over decades of use. The debate over the cost-effectiveness and clinical added value of NaF PET/CT continues.

F-18 Fluciclovine (Axumin)

Mechanism

F-18 fluciclovine is a synthetic amino acid analog (anti-1-amino-3-[F-18]fluorocyclobutane-1-carboxylic acid) that is transported into cells by amino acid transporters LAT1 and ASCT2, both of which are upregulated in prostate cancer. It is not metabolized intracellularly but accumulates in cells with increased amino acid transport activity. A key advantage is its low urinary excretion, which provides cleaner visualization of the pelvis compared to PSMA agents.

Clinical Applications

Fluciclovine has been used primarily for biochemical recurrence of prostate cancer, though it is increasingly being supplanted by PSMA PET agents, which offer higher sensitivity and specificity, particularly at low PSA levels. The normal biodistribution includes highest uptake in the liver, followed by the pancreas, bone marrow, skeletal muscle, and salivary glands, with minimal urinary excretion. Pitfalls include bone marrow uptake that can obscure subtle marrow metastases, uptake in benign prostatic hyperplasia, and inflammatory processes.

C-11 Choline and F-18 Fluorocholine

Mechanism

Choline is a precursor to phosphatidylcholine, a major component of cell membranes. Prostate cancer cells exhibit increased choline kinase activity and accelerated membrane synthesis, driving higher choline uptake. C-11 choline has a 20-minute half-life requiring an on-site cyclotron, while F-18 fluorocholine has a 110-minute half-life permitting distribution from centralized production sites.

Clinical Applications

Choline PET was previously used for biochemical recurrence of prostate cancer but has been largely replaced by PSMA agents. Choline tracers retain utility in evaluating well-differentiated hepatocellular carcinoma (which takes up choline but not FDG) and in localizing parathyroid adenomas (F-18 fluorocholine PET/CT is increasingly used for this indication). The normal biodistribution includes liver, kidneys, pancreas, and salivary glands, with renal excretion.

F-18 FDOPA

Mechanism

F-18 FDOPA is an analog of L-DOPA that enters cells through the large neutral amino acid transporter (LAT) and is decarboxylated intracellularly by amino acid decarboxylase (AADC), trapping the tracer within the cell. It reflects the catecholamine synthesis pathway.

Clinical Applications

FDOPA has a remarkably diverse range of indications. In neuroendocrine tumors, it serves as an alternative to Ga-68 DOTATATE, with particular utility in medullary thyroid cancer. For pheochromocytoma and paraganglioma, it is especially valuable when MIBG scintigraphy is negative. In congenital hyperinsulinism, FDOPA PET is the definitive imaging method for differentiating focal from diffuse pancreatic disease in neonates, directly guiding surgical planning. As an amino acid PET agent, it is used in brain tumor imaging to differentiate recurrence from radiation necrosis. In movement disorders, it evaluates presynaptic dopaminergic function similarly to DaTscan. The normal biodistribution includes the striatum (basal ganglia), kidneys/bladder, pancreas, and mild liver uptake.

F-18 FET and C-11 Methionine (Amino Acid Brain PET)

F-18 FET (Fluoroethyltyrosine)

F-18 FET is an amino acid analog transported into cells by LAT transporters. Unlike natural amino acids, it accumulates in brain tumors but is not metabolized, making it purely a transport marker. Because normal brain tissue has very low FET uptake, the tumor-to-background contrast is excellent -- a major advantage over FDG, which suffers from high physiologic cortical uptake. FET is used extensively in Europe for brain tumor grading, distinguishing recurrence from treatment effect, and guiding stereotactic biopsy.

C-11 Methionine

C-11 methionine is a natural amino acid that reflects protein synthesis rates. Its short 20-minute half-life necessitates an on-site cyclotron. It is well-established for brain tumor imaging, with relatively low normal brain uptake compared to tumor tissue, providing good contrast for lesion detection.

Emerging PET Agents

F-18 FLT (Fluorothymidine)

F-18 FLT is a thymidine analog that reflects cellular proliferation through thymidine kinase 1 activity. It is phosphorylated and trapped intracellularly, and its uptake correlates with the Ki-67 proliferation index. FLT is primarily used in research for early therapy response assessment.

Ga-68/F-18 FAPI (Fibroblast Activation Protein Inhibitor)

FAPI tracers target fibroblast activation protein (FAP), which is expressed on cancer-associated fibroblasts in the tumor stroma rather than on the tumor cells themselves. FAPI agents demonstrate very high tumor-to-background ratios because normal tissues have minimal FAP expression, producing remarkably clean images. FAPI PET shows promise in pancreatic, colorectal, breast, and head-and-neck cancers, and may detect cancers with low FDG avidity. However, FAPI also accumulates in fibrotic and healing tissues, including post-myocardial infarction cardiac tissue, liver cirrhosis, and arthritic joints.

Cu-64 DOTATATE

Cu-64 DOTATATE has a significantly longer half-life (12.7 hours) than Ga-68 DOTATATE, allowing delayed imaging for improved target-to-background ratios, and its lower positron energy provides higher spatial resolution. Cu-64 can be paired with Cu-67 for theranostic applications. It is FDA-approved for NET imaging.

<image>A comparison panel showing the normal biodistribution patterns of six major non-FDG PET tracers on maximum intensity projection images: Ga-68 DOTATATE (spleen, adrenals, pituitary, kidneys), PSMA (lacrimal glands, salivary glands, kidneys, small bowel, liver), F-18 NaF (skeleton, kidneys), F-18 fluciclovine (liver, pancreas, marrow), F-18 FDOPA (striatum, kidneys, pancreas), and F-18 FAPI (low background, minimal physiologic uptake). Label key organs for each tracer.</image>

<image>A molecular targeting diagram showing the specific cellular targets and uptake mechanisms of non-FDG PET tracers. Illustrate a cancer cell with its surface receptors and intracellular pathways: GLUT transporter (FDG), somatostatin receptor (DOTATATE), PSMA enzyme (PSMA agents), LAT transporter (fluciclovine, FDOPA), thymidine kinase (FLT), choline kinase (choline), and FAP on adjacent cancer-associated fibroblasts (FAPI). Show each tracer binding to or entering through its respective target.</image>

Clinical Pearls

Ga-68 DOTATATE has replaced In-111 octreotide (OctreoScan) for neuroendocrine tumor imaging, offering dramatically better sensitivity, spatial resolution, and patient convenience (a 2-hour study versus the 24 to 48 hours required for OctreoScan).

The pancreatic uncinate process normally expresses SSTR2, producing focal uptake on DOTATATE PET that is a well-recognized normal variant and should not be mistaken for a neuroendocrine tumor.

PSMA PET has largely replaced fluciclovine and choline PET for prostate cancer biochemical recurrence due to superior sensitivity, especially at low PSA levels below 0.5 ng/mL.

PSMA is not prostate-specific. It is expressed in other cancers, ganglia, and some benign conditions. Celiac ganglion uptake is a well-known mimic of retroperitoneal lymph node metastasis that requires awareness to avoid misinterpretation.

F-18 NaF PET/CT detects more skeletal metastases than Tc-99m bone scan, but it has not been widely adopted because of cost concerns and uncertain impact on patient management and outcomes.

FAPI is an exciting emerging tracer with near-universal tumor uptake and very low background activity, potentially complementing or replacing FDG in certain clinical settings, though its uptake in fibrotic and healing tissues must be recognized.

For brain tumor imaging, amino acid PET tracers (FET, methionine, FDOPA) are superior to FDG because normal cortex has high FDG uptake but low amino acid uptake, providing much better tumor-to-background contrast.

References

• Hofman MS, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer. Lancet. 2020;395(10231):1208-1216.
• Hope TA, et al. SNMMI procedure standard/EANM practice guideline for SSTR PET. J Nucl Med. 2023;64(2):204-210.
• Basu S, et al. PET and PET/CT in non-FDG oncology. Nucl Med Commun. 2023;44(1):1-15.
• Kratochwil C, et al. FAPI PET/CT: current status and future directions. Eur J Nucl Med Mol Imaging. 2021;48(12):4187-4195.

Read this lecture as Markdown